Key result
Cardioneuroablation emerges as a potential management strategy for cardioinhibitory vasovagal syncope.
Why the study?
Treatment of vasovagal syncope is challenging, as pharmacological and interventional therapies as well as cardiac pacing have shown limited efficacy.
Cardioneuroablation may expand options for refractory cardioinhibitory vasovagal syncope; leaves open the need for prospective trials to confirm safety and efficacy.
Reflex syncope, also known as neurocardiogenic or vasovagal syncope (VVS), is the most frequent etiology of syncope in young people without apparent cardiac or neurological pathology.1–3 Cardioinhibitory response with prolonged asystole and/or transient atrioventricular block induced by a massive vagal reflex is commonly observed in severely symptomatic cases. The treatment of VVS is challenging. Multicenter placebo-controlled trials published to date have shown limited efficacy of pharmacological and interventional therapies as well as cardiac pacing.
No takes yet. Share an insight, caveat, or question.
Stec et al. (2020) conducted a review in Cardioinhibitory vasovagal syncope. Cardioneuroablation was evaluated. Cardioneuroablation is discussed as a management strategy for cardioinhibitory vasovagal syncope, a condition for which previous therapies have shown limited efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: